跳至主要内容
临床试验/NL-OMON43113
NL-OMON43113尚未招募不适用

ong-term follow-up after Instrumented Bone Preserving (IBP) total elbow arthroplasty using RadioStereometric Analysis (RSA). - Long-term follow-up IBP prothesis using RSA

Sint Maartenskliniek0 个研究点目标入组 16 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
16

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 64(—)

入选标准

  • - Received an IBP total elbow prosthesis between June 2003 and February 2006.
  • - Participated in the study assessing the short-term results of the IBP total elbow prosthesis
  • - Sign informed consent for the proposed study.

排除标准

  • 未提供

研究者

相似试验

撤回
不适用
Post-operative longitudinal monitoring of osteochondral defects of the talus with ultrasound after bone marrow stimulation.
NL-OMON45273Orthopedie5
招募中
不适用
ong-term follow up study after transplantation of human iPSC-derived dopaminergic progenitors in the treatment of Parkinson's DiseaseParkinson's disease
JPRN-UMIN000048476Kyoto University Hospital7
已完成
不适用
ong-term follow up after implantation of Artisan Phakic Iris Claw Intraocular lens for the correction of high degree myopiashortsightedness1001591710043413myopia
NL-OMON39608Academisch Medisch Centrum200
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149
NL-OMON56013Sangamo Therapeutics France SAS8
进行中(未招募)
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2022-002440-40-DESangamo Therapeutics France SAS15